The U.S. operations of a Swiss pharmaceutical maker has shut down nearly 200 blood plasma donation centers while the company responds to "network issues"
The U.S. operations of a Swiss pharmaceutical maker has shut down nearly 200 blood plasma donation centers while the company responds to "network issues"
While Octapharma drug Balfaxar met the goal of its pivotal clinical trial, more deaths and blood clot problems were reported in the study drug arm versus the comparator group. The FDA is requiring a post-marketing study to further assess the drug’s risks.
Real-world data and expert perspectives on state-of-the-art clinical practice for the management of infection in patients with CLL will be showcased during the Octapharma Update-in-Hematology session
LACHEN, Switzerland, June 6, 2023 /PRNewswire/ Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 CongressNew